You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTrazodone
Accession NumberDB00656  (APRD00533)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionA serotonin uptake inhibitor that is used as an antidepressive agent. It has been shown to be effective in patients with major depressive disorders and other subsets of depressive disorders. It is generally more useful in depressive disorders associated with insomnia and anxiety. This drug does not aggravate psychotic symptoms in patients with schizophrenia or schizoaffective disorders. (From AMA Drug Evaluations Annual, 1994, p309)
Structure
Thumb
Synonyms
2-(3-[4-(3-Chlorophenyl)-1-piperazinyl]propyl)[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one
Trazodona
Trazodone
Trazodonum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Desyrel Dividose Tab 300mgtablet300 mgoralBristol Labs Division Of Bristol Myers Squibb1989-12-311999-08-09Canada
Desyrel Dividose Tablet 150 mgtablet150 mgoralBristol Myers Squibb Canada1988-12-312010-01-05Canada
Desyrel Tab 100mgtablet100 mgoralBristol Myers Squibb Canada1983-12-312010-09-07Canada
Desyrel Tab 50mgtablet50 mgoralBristol Myers Squibb Canada1983-12-312010-05-14Canada
Dom-trazodone Tablets - 50mgtablet50 mgoralDominion Pharmacal1996-12-31Not applicableCanada
Dom-trazodone Tablets-100mgtablet100 mgoralDominion Pharmacal1996-12-31Not applicableCanada
Mar-trazodonetablet150 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Mar-trazodonetablet50 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Mar-trazodonetablet100 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Mylan-trazodonetablet150 mgoralMylan Pharmaceuticals Ulc1997-11-282016-06-28Canada
Mylan-trazodonetablet50 mgoralMylan Pharmaceuticals Ulc1997-09-052016-06-28Canada
Mylan-trazodonetablet100 mgoralMylan Pharmaceuticals Ulc1997-09-052016-06-28Canada
Ntp-trazodonetablet100 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-trazodonetablet150 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-trazodonetablet50 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Nu-trazodone - Tab 100mgtablet100 mgoralNu Pharm Inc1995-12-312012-09-04Canada
Nu-trazodone - Tab 50mgtablet50 mgoralNu Pharm Inc1995-12-312012-09-04Canada
Nu-trazodone-D - Tab 150mgtablet150 mgoralNu Pharm Inc1995-12-312012-09-04Canada
Oleptrotablet (extended-release)300 mgoralAngelini Pharma Inc2011-03-09Not applicableCanada
Oleptrotablet, extended release150 mg/1oralAngelini Pharma Inc.2010-02-022016-03-29Us
Oleptrotablet, extended release300 mg/1oralAngelini Pharma Inc.2010-02-022016-03-29Us
Oleptrotablet (extended-release)150 mgoralAngelini Pharma Inc2011-03-09Not applicableCanada
Penta-trazodone Tabletstablet50 mgoralPentapharm Ltd.Not applicableNot applicableCanada
Penta-trazodone Tabletstablet100 mgoralPentapharm Ltd.Not applicableNot applicableCanada
Penta-trazodone Tabletstablet150 mgoralPentapharm Ltd.Not applicableNot applicableCanada
PHL-trazodonetablet50 mgoralPharmel Inc1998-02-17Not applicableCanada
PHL-trazodonetablet100 mgoralPharmel Inc1998-02-17Not applicableCanada
PMS Trazodone HCl Tab 100mgtablet100 mgoralPharmascience Inc1993-12-31Not applicableCanada
PMS Trazodone HCl Tab 50mgtablet50 mgoralPharmascience Inc1993-12-31Not applicableCanada
PMS-trazodonetablet68.25 mgoralPharmascience Inc1998-02-17Not applicableCanada
Ratio-trazodonetablet50 mgoralTeva Canada Limited2006-03-10Not applicableCanada
Ratio-trazodonetablet100 mgoralTeva Canada Limited2006-03-10Not applicableCanada
Ratio-trazodonetablet150 mgoralTeva Canada Limited2006-03-10Not applicableCanada
Ratio-trazodone Tab 150mgtablet150 mgoralRatiopharm Inc Division Of Teva Canada Limited1994-12-312009-01-22Canada
Ratio-trazodone Tablets 100mgtablet100 mgoralRatiopharm Inc Division Of Teva Canada Limited1994-12-312009-01-22Canada
Ratio-trazodone Tablets 50mgtablet50 mgoralRatiopharm Inc Division Of Teva Canada Limited1994-12-312009-01-22Canada
Scheinpharm Trazodonetablet100 mgoralSchein Pharmaceutical Canada Inc.2000-09-132004-07-26Canada
Scheinpharm Trazodonetablet50 mgoralSchein Pharmaceutical Canada Inc.2000-09-132004-07-26Canada
Teva-trazodonetablet100 mgoralTeva Canada Limited1995-12-31Not applicableCanada
Teva-trazodonetablet50 mgoralTeva Canada Limited1995-12-31Not applicableCanada
Teva-trazodonetablet150 mgoralTeva Canada Limited1995-12-31Not applicableCanada
Trazodonetablet100 mgoralSanis Health Inc2010-04-30Not applicableCanada
Trazodonetablet150 mgoralSanis Health Inc2010-04-30Not applicableCanada
Trazodonetablet50 mgoralSanis Health Inc2010-04-30Not applicableCanada
Trazodone - 100 - Tab 100mgtablet100 mgoralPro Doc Limitee1996-12-31Not applicableCanada
Trazodone-150 D - Tab 150mgtablet150 mgoralPro Doc Limitee1996-12-31Not applicableCanada
Trazodone-50 - Tab 50mgtablet50 mgoralPro Doc Limitee1996-12-31Not applicableCanada
Trazoreltablet100 mgoralValeant Canada Lp Valeant Canada S.E.C.1997-03-072014-07-30Canada
Trazoreltablet150 mgoralValeant Canada Lp Valeant Canada S.E.C.1997-02-042014-07-30Canada
Trazoreltablet50 mgoralValeant Canada Lp Valeant Canada S.E.C.1997-02-042014-07-30Canada
Zym-trazodonetablet50 mgoralZymcan Pharmaceuticals Inc2009-06-232014-06-16Canada
Zym-trazodonetablet100 mgoralZymcan Pharmaceuticals Inc2009-06-232014-06-16Canada
Zym-trazodonetablet68.25 mgoralZymcan Pharmaceuticals Inc2004-04-062014-06-16Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-trazodone D Tablets 150mgtablet150 mgoralApotex Inc1995-12-31Not applicableCanada
Apo-trazodone Tablets 100mgtablet100 mgoralApotex Inc1995-12-31Not applicableCanada
Apo-trazodone Tablets 50mgtablet50 mgoralApotex Inc1995-12-31Not applicableCanada
Trazodonetablet100 mg/1oralPd Rx Pharmaceuticals, Inc.2010-01-01Not applicableUs
Trazodonetablet50 mg/1oralNorthwind Pharmaceuticals, LLC2014-12-01Not applicableUs
Trazodone Hydrochloridetablet100 mg/1oralMajor Pharmaceuticals2004-02-03Not applicableUs
Trazodone Hydrochloridetablet150 mg/1oralPhysicians Total Care, Inc.1992-02-20Not applicableUs
Trazodone Hydrochloridetablet100 mg/1oralREMEDYREPACK INC.2013-03-27Not applicableUs
Trazodone Hydrochloridetablet100 mg/1oralClinical Solutions Wholesale1990-09-30Not applicableUs
Trazodone Hydrochloridetablet100 mg/1oralProficient Rx LP1990-09-30Not applicableUs
Trazodone Hydrochloridetablet50 mg/1oralKeltman Pharmaceuticals Inc.2010-11-17Not applicableUs
Trazodone Hydrochloridetablet50 mg/1oralLake Erie Medical DBA Quality Care Products LLC2011-12-14Not applicableUs
Trazodone Hydrochloridetablet50 mg/1oralMajor Pharmaceuticals2008-11-17Not applicableUs
Trazodone Hydrochloridetablet50 mg/1oralKAISER FOUNDATION HOSPITALS1987-12-22Not applicableUs
Trazodone Hydrochloridetablet, film coated50 mg/1oralMutual Pharmaceutical Company, Inc.1993-03-24Not applicableUs
Trazodone Hydrochloridetablet300 mg/1oralTorrent Pharmaceuticals Limited2013-11-27Not applicableUs
Trazodone Hydrochloridetablet100 mg/1oralCardinal Health1990-09-30Not applicableUs
Trazodone Hydrochloridetablet300 mg/1oralApotex Corp2009-01-05Not applicableUs
Trazodone Hydrochloridetablet50 mg/1oralContract Pharmacy Services Pa2010-08-11Not applicableUs
Trazodone Hydrochloridetablet300 mg/1oralAv Kare, Inc.2014-02-06Not applicableUs
Trazodone Hydrochloridetablet, film coated100 mg/1oralREMEDYREPACK INC.2016-01-07Not applicableUs
Trazodone Hydrochloridetablet100 mg/1oralTYA Pharmaceuticals1990-09-30Not applicableUs
Trazodone Hydrochloridetablet100 mg/1oralPreferred Pharmaceuticals, Inc2012-02-28Not applicableUs
Trazodone Hydrochloridetablet150 mg/1oralPliva Inc.1990-09-30Not applicableUs
Trazodone Hydrochloridetablet150 mg/1oralBlenheim Pharmacal, Inc.2014-05-22Not applicableUs
Trazodone Hydrochloridetablet50 mg/1oralCardinal Health2011-01-202016-03-11Us
Trazodone Hydrochloridetablet150 mg/1oralAidarex Pharmaceuticals LLC1990-09-30Not applicableUs
Trazodone Hydrochloridetablet150 mg/1oralGolden State Medical Supply, Inc.2008-11-17Not applicableUs
Trazodone Hydrochloridetablet50 mg/1oralPd Rx Pharmaceuticals, Inc.1990-09-30Not applicableUs
Trazodone Hydrochloridetablet100 1/1oralDIRECT RX2014-01-01Not applicableUs
Trazodone Hydrochloridetablet, film coated50 mg/1oralAmerican Health Packaging2013-12-16Not applicableUs
Trazodone Hydrochloridetablet100 mg/1oralREMEDYREPACK INC.2010-09-28Not applicableUs
Trazodone Hydrochloridetablet50 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2011-01-20Not applicableUs
Trazodone Hydrochloridetablet, film coated100 mg/1oralA S Medication Solutions Llc2010-05-30Not applicableUs
Trazodone Hydrochloridetablet50 mg/1oralRebel Distributors Corp.1987-12-11Not applicableUs
Trazodone Hydrochloridetablet100 mg/1oralBlenheim Pharmacal, Inc.2012-01-18Not applicableUs
Trazodone Hydrochloridetablet50 mg/1oralDispensing Solutions, Inc.2011-01-20Not applicableUs
Trazodone Hydrochloridetablet50 mg/1oralREMEDYREPACK INC.2013-03-27Not applicableUs
Trazodone Hydrochloridetablet150 mg/1oralClinical Solutions Wholesale1990-09-30Not applicableUs
Trazodone Hydrochloridetablet, film coated50 mg/1oralbryant ranch prepack2010-05-30Not applicableUs
Trazodone Hydrochloridetablet100 mg/1oralKeltman Pharmaceuticals Inc.2010-11-17Not applicableUs
Trazodone Hydrochloridetablet150 mg/1oralLake Erie Medical DBA Quality Care Products LLC1990-09-30Not applicableUs
Trazodone Hydrochloridetablet100 mg/1oralMajor Pharmaceuticals2008-11-17Not applicableUs
Trazodone Hydrochloridetablet300 mg/1oralBarr Laboratories Inc.1999-05-03Not applicableUs
Trazodone Hydrochloridetablet, film coated100 mg/1oralMutual Pharmaceutical Company, Inc.1993-03-24Not applicableUs
Trazodone Hydrochloridetablet50 mg/1oralSTAT RX LLC USA1987-12-11Not applicableUs
Trazodone Hydrochloridetablet150 mg/1oralCardinal Health1990-09-30Not applicableUs
Trazodone Hydrochloridetablet150 mg/1oralApotex Corp2014-12-31Not applicableUs
Trazodone Hydrochloridetablet50 mg/1oralContract Pharmacy Services Pa2010-03-09Not applicableUs
Trazodone Hydrochloridetablet50 mg/1oralSTAT Rx USA LLC2008-11-17Not applicableUs
Trazodone Hydrochloridetablet150 mg/1oralAvera Mc Kennan Hospital2015-04-17Not applicableUs
Trazodone Hydrochloridetablet100 mg/1oralCardinal Health2011-01-202016-03-11Us
Trazodone Hydrochloridetablet50 mg/1oralAv Kare, Inc.2014-02-06Not applicableUs
Trazodone Hydrochloridetablet50 mg/1oralApotex Corp2008-11-17Not applicableUs
Trazodone Hydrochloridetablet, film coated50 mg/1oralMed Vantx, Inc.1993-03-24Not applicableUs
Trazodone Hydrochloridetablet50 mg/1oralPreferred Pharmaceuticals, Inc2012-02-28Not applicableUs
Trazodone Hydrochloridetablet100 mg/1oralUnit Dose Services2011-01-20Not applicableUs
Trazodone Hydrochloridetablet50 mg/1oralTorrent Pharmaceuticals Limited2013-11-27Not applicableUs
Trazodone Hydrochloridetablet50 mg/1oralPhysicians Total Care, Inc.1996-04-09Not applicableUs
Trazodone Hydrochloridetablet100 mg/1oralRebel Distributors Corp.1987-12-11Not applicableUs
Trazodone Hydrochloridetablet150 mg/1oralDIRECT RX2014-01-01Not applicableUs
Trazodone Hydrochloridetablet, film coated100 mg/1oralAmerican Health Packaging2013-12-16Not applicableUs
Trazodone Hydrochloridetablet150 mg/1oralREMEDYREPACK INC.2010-10-26Not applicableUs
Trazodone Hydrochloridetablet50 mg/1oralCarilion Materials Management1990-09-30Not applicableUs
Trazodone Hydrochloridetablet100 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2011-01-20Not applicableUs
Trazodone Hydrochloridetablet150 mg/1oralBlenheim Pharmacal, Inc.2010-03-03Not applicableUs
Trazodone Hydrochloridetablet50 mg/1oralCardinal Health2004-02-03Not applicableUs
Trazodone Hydrochloridetablet50 mg/1oralAidarex Pharmaceuticals LLC1990-09-30Not applicableUs
Trazodone Hydrochloridetablet50 mg/1oralGolden State Medical Supply, Inc.2008-11-17Not applicableUs
Trazodone Hydrochloridetablet150 mg/1oralbryant ranch prepack1990-09-30Not applicableUs
Trazodone Hydrochloridetablet50 mg/1oralLegacy Pharmaceutical Packaging2008-11-17Not applicableUs
Trazodone Hydrochloridetablet50 mg/1oralPliva Inc.1990-09-30Not applicableUs
Trazodone Hydrochloridetablet, film coated150 mg/1oralA S Medication Solutions1993-03-24Not applicableUs
Trazodone Hydrochloridetablet, film coated50 mg/1oralQualitest Pharmaceuticals2010-05-30Not applicableUs
Trazodone Hydrochloridetablet, film coated150 mg/1oralMutual Pharmaceutical Company, Inc.1993-03-24Not applicableUs
Trazodone Hydrochloridetablet100 mg/1oralSTAT RX LLC USA1987-12-11Not applicableUs
Trazodone Hydrochloridetablet100 mg/1oralCardinal Health2008-11-17Not applicableUs
Trazodone Hydrochloridetablet, film coated50 mg/1oralREMEDYREPACK INC.2015-11-12Not applicableUs
Trazodone Hydrochloridetablet100 mg/1oralContract Pharmacy Services Pa2010-03-09Not applicableUs
Trazodone Hydrochloridetablet, film coated50 mg/1oralAphena Pharma Solutions Tennessee, Llc2010-05-30Not applicableUs
Trazodone Hydrochloridetablet150 mg/1oralCardinal Health1990-09-30Not applicableUs
Trazodone Hydrochloridetablet100 mg/1oralAv Kare, Inc.2014-02-06Not applicableUs
Trazodone Hydrochloridetablet100 mg/1oralApotex Corp2008-11-17Not applicableUs
Trazodone Hydrochloridetablet50 mg/1oralMed Vantx, Inc.2011-01-20Not applicableUs
Trazodone Hydrochloridetablet50 mg/1oralMc Kesson Contract Packaging2011-10-11Not applicableUs
Trazodone Hydrochloridetablet50 mg/1oralUnit Dose Services2011-01-20Not applicableUs
Trazodone Hydrochloridetablet100 mg/1oralTorrent Pharmaceuticals Limited2013-11-27Not applicableUs
Trazodone Hydrochloridetablet50 mg/1oralMajor Pharmaceuticals2004-02-03Not applicableUs
Trazodone Hydrochloridetablet100 mg/1oralPhysicians Total Care, Inc.1997-05-08Not applicableUs
Trazodone Hydrochloridetablet150 mg/1oralRebel Distributors Corp.1988-03-09Not applicableUs
Trazodone Hydrochloridetablet50 mg/1oralClinical Solutions Wholesale1990-09-30Not applicableUs
Trazodone Hydrochloridetablet50 mg/1oralProficient Rx LP1990-09-30Not applicableUs
Trazodone Hydrochloridetablet150 mg/1oralAmerican Health Packaging2012-09-03Not applicableUs
Trazodone Hydrochloridetablet100 mg/1oralLake Erie Medical DBA Quality Care Products LLC2011-12-14Not applicableUs
Trazodone Hydrochloridetablet150 mg/1oralCarilion Materials Management1990-09-30Not applicableUs
Trazodone Hydrochloridetablet, film coated50 mg/1oralProficient Rx LP2010-05-30Not applicableUs
Trazodone Hydrochloridetablet50 mg/1oralBlenheim Pharmacal, Inc.2011-04-01Not applicableUs
Trazodone Hydrochloridetablet100 mg/1oralCardinal Health2004-02-03Not applicableUs
Trazodone Hydrochloridetablet100 mg/1oralAidarex Pharmaceuticals LLC1990-09-30Not applicableUs
Trazodone Hydrochloridetablet100 mg/1oralGolden State Medical Supply, Inc.2008-11-17Not applicableUs
Trazodone Hydrochloridetablet100 mg/1oralbryant ranch prepack2011-01-20Not applicableUs
Trazodone Hydrochloridetablet100 mg/1oralLegacy Pharmaceutical Packaging2008-11-17Not applicableUs
Trazodone Hydrochloridetablet100 mg/1oralPliva Inc.1990-09-30Not applicableUs
Trazodone Hydrochloridetablet100 mg/1oralContract Pharmacy Services Pa2010-08-11Not applicableUs
Trazodone Hydrochloridetablet, film coated100 mg/1oralAphena Pharma Solutions Tennessee, Llc2010-05-30Not applicableUs
Trazodone Hydrochloridetablet, film coated100 mg/1oralQualitest Pharmaceuticals2010-05-30Not applicableUs
Trazodone Hydrochloridetablet, film coated50 mg/1oralA S Medication Solutions Llc2010-05-30Not applicableUs
Trazodone Hydrochloridetablet150 mg/1oralSTAT RX LLC USA1988-03-09Not applicableUs
Trazodone Hydrochloridetablet150 mg/1oralPd Rx Pharmaceuticals, Inc.1990-09-30Not applicableUs
Trazodone Hydrochloridetablet50 mg/1oralDIRECT RX2014-01-01Not applicableUs
Trazodone Hydrochloridetablet150 mg/1oralTorrent Pharmaceuticals Limited2013-11-27Not applicableUs
Trazodone Hydrochloridetablet50 mg/1oralCardinal Health1990-09-30Not applicableUs
Trazodone Hydrochloridetablet150 mg/1oralAv Kare, Inc.2014-02-06Not applicableUs
Trazodone Hydrochloridetablet150 mg/1oralApotex Corp2008-11-17Not applicableUs
Trazodone Hydrochloridetablet50 mg/1oralDispensing Solutions, Inc.2011-01-20Not applicableUs
Trazodone Hydrochloridetablet100 mg/1oralMc Kesson Contract Packaging2012-01-25Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
BeneficatNot Available
DepraxNot Available
DesirelNot Available
DesyrelBristol-Myers Squibb
Desyrel DividoseBristol-Myers Squibb
MesyrelNot Available
MolipaxinNot Available
ThombranNot Available
TrialodineNot Available
TritticoNot Available
Brand mixtures
NameLabellerIngredients
TrazaminePhysician Therapeutics Llc
Salts
Name/CASStructureProperties
Trazodone Hydrochloride
25332-39-2
Thumb
  • InChI Key: OHHDIOKRWWOXMT-UHFFFAOYSA-N
  • Monoisotopic Mass: 407.127965797
  • Average Mass: 408.325
DBSALT000344
Categories
UNIIYBK48BXK30
CAS number19794-93-5
WeightAverage: 371.864
Monoisotopic: 371.151288058
Chemical FormulaC19H22ClN5O
InChI KeyInChIKey=PHLBKPHSAVXXEF-UHFFFAOYSA-N
InChI
InChI=1S/C19H22ClN5O/c20-16-5-3-6-17(15-16)23-13-11-22(12-14-23)8-4-10-25-19(26)24-9-2-1-7-18(24)21-25/h1-3,5-7,9,15H,4,8,10-14H2
IUPAC Name
2-{3-[4-(3-chlorophenyl)piperazin-1-yl]propyl}-2H,3H-[1,2,4]triazolo[4,3-a]pyridin-3-one
SMILES
ClC1=CC=CC(=C1)N1CCN(CCCN2N=C3C=CC=CN3C2=O)CC1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylpiperazines. These are compounds containing a phenylpiperazine skeleton, which consists of a piperazine bound to a phenyl group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassDiazinanes
Sub ClassPiperazines
Direct ParentPhenylpiperazines
Alternative Parents
Substituents
  • N-arylpiperazine
  • Phenylpiperazine
  • Triazolopyridine
  • Substituted aniline
  • Dialkylarylamine
  • N-alkylpiperazine
  • Pyridinone
  • Halobenzene
  • Chlorobenzene
  • Aniline
  • Benzenoid
  • Pyridine
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl chloride
  • Heteroaromatic compound
  • 1,2,4-triazole
  • Triazole
  • Azole
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of depression.
PharmacodynamicsTrazodone is an antidepressant and hypnotic chemically unrelated to tricyclic, tetracyclic, or other known antidepressant agents. The mechanism of trazodone's antidepressant action in man is not fully understood. In animals, trazodone selectively inhibits serotonin uptake by brain synaptosomes and potentiates the behavioral changes induced by the serotonin precursor, 5-hydroxytryptophan. Cardiac conduction effects of trazodone in the anesthetized dog are qualitatively dissimilar and quantitatively less pronounced than those seen with tricyclic antidepressants. Trazodone is not a monoamine oxidase inhibitor and, unlike amphetamine-type drugs, does not stimulate the central nervous system. In man, trazodone is well absorbed after oral administration without selective localization in any tissue. Since the clearance of trazodone from the body is sufficiently variable, in some patients trazodone may accumulate in the plasma.
Mechanism of actionTrazodone binds at 5-HT2 receptor, it acts as a serotonin agonist at high doses and a serotonin antagonist at low doses. Like fluoxetine, trazodone's antidepressant activity likely results from blockage of serotonin reuptake by inhibiting serotonin reuptake pump at the presynaptic neuronal membrane. If used for long time periods, postsynaptic neuronal receptor binding sites may also be affected. The sedative effect of trazodone is likely the result of alpha-adrenergic blocking action and modest histamine blockade at H1 receptor. It weakly blocks presynaptic alpha2-adrenergic receptors and strongly inhibits postsynaptic alpha1 receptors. Trazodone does not affect the reuptake of norepinephrine or dopamine within the CNS.
Related Articles
AbsorptionRapidly and almost completely absorbed following oral administration. Food may decrease the rate and extent of absorption.
Volume of distributionNot Available
Protein binding89-95% bound to plasma proteins in vitro
Metabolism

Undergoes extensive hepatic metabolism via hydroxylation, N-dealkylation, N-oxidation and splitting of the pyridine ring. Cytochrome P450 (CYP) 3A4 catalyzes the formation of the major active metabolite, m-chlorophenylpiperazine (m-CPP). Metabolites may be further conjugated to glucuonic acid or glutathione. CYP2D6 is responsible for 4'-hydroxylation of m-CPP and the formation of at least one glutathione conjugates of m-CPP, a quinone imine-sulhydryl adduct. Oxotriazolopyridinpropionic acid, an inactive metabolite, and its conjugates account for about 20% of the total excreted oral dose. Less than 1% of the oral dose is excreted unchanged. Approximately 70-75% of the dose is eliminated in urine with the remainder being excreted in feces via biliary elimination.

SubstrateEnzymesProduct
Trazodone
4'-hydroxytrazodone glutathione Details
Trazodone
m-chlorophenylpiperazine (m-CPP) Details
Trazodone
triazolopropionic acidDetails
Trazodone
triazolopyridinone epoxideDetails
Trazodone
4'-hydroxytrazodone Details
Trazodone
Not Available
GlutathioneDetails
Trazodone
Not Available
Glucuonic acidDetails
Trazodone
Not Available
Oxotriazolopyridinpropionic acidDetails
Route of eliminationNot Available
Half lifeUndergoes biphasic elimination with an initial phase t1/2 α of 3-6 hours and a terminal phase t1/2 β of 5-9 hours.
ClearanceNot Available
ToxicityLD50=96mg/kg (i.v. in mice)
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9829
Caco-2 permeable-0.6166
P-glycoprotein substrateSubstrate0.547
P-glycoprotein inhibitor IInhibitor0.8634
P-glycoprotein inhibitor IIInhibitor0.8889
Renal organic cation transporterInhibitor0.6479
CYP450 2C9 substrateNon-substrate0.7897
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateSubstrate0.7408
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.6613
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.83
Ames testNon AMES toxic0.5133
CarcinogenicityNon-carcinogens0.8545
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.7007 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.8994
hERG inhibition (predictor II)Inhibitor0.7503
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Labopharm inc
  • Apothecon inc div bristol myers squibb
  • Alvogen inc
  • American therapeutics inc
  • Apotex inc
  • Matrix laboratories ltd
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Pliva inc
  • Quantum pharmics ltd
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Usl pharma inc
  • Vintage pharmaceuticals llc
  • Watson laboratories inc
Packagers
Dosage forms
FormRouteStrength
Tabletoral150 mg
Tabletoral50 mg
Tabletoral300 mg
Tablet (extended-release)oral150 mg
Tablet (extended-release)oral300 mg
Tablet, extended releaseoral150 mg/1
Tablet, extended releaseoral300 mg/1
Tabletoral100 mg
Tabletoral68.25 mg
Kit
Tabletoral100 1/1
Tabletoral100 mg/1
Tabletoral150 mg/1
Tabletoral300 mg/1
Tabletoral50 mg/1
Tablet, film coatedoral100 mg/1
Tablet, film coatedoral150 mg/1
Tablet, film coatedoral50 mg/1
Prices
Unit descriptionCostUnit
Trazodone hcl powder8.26USD g
Desyrel 300 mg tablet6.03USD tablet
TraZODone HCl 300 mg tablet5.65USD tablet
Trazodone 300 mg tablet5.44USD tablet
Desyrel 100 mg tablet4.6USD tablet
Desyrel 150 mg tablet3.39USD tablet
TraZODone HCl 150 mg tablet1.53USD tablet
Trazodone 150 mg tablet1.47USD tablet
Desyrel 50 mg tablet1.33USD tablet
TraZODone HCl 100 mg tablet0.76USD tablet
Trazodone 100 mg tablet0.73USD tablet
Apo-Trazodone D 150 mg Tablet0.61USD tablet
Desyrel Dividose 150 mg Tablet0.61USD tablet
Novo-Trazodone 150 mg Tablet0.61USD tablet
Nu-Trazodone-D 150 mg Tablet0.61USD tablet
Ratio-Trazodone 150 mg Tablet0.61USD tablet
TraZODone HCl 50 mg tablet0.59USD tablet
Trazodone 50 mg tablet0.57USD tablet
Nu-Trazodone 100 mg Tablet0.41USD tablet
Pms-Trazodone 100 mg Tablet0.41USD tablet
Ratio-Trazodone 100 mg Tablet0.41USD tablet
Apo-Trazodone 100 mg Tablet0.41USD tablet
Desyrel 100 mg Tablet0.41USD tablet
Mylan-Trazodone 100 mg Tablet0.41USD tablet
Novo-Trazodone 100 mg Tablet0.41USD tablet
Pms-Trazodone 75 mg Tablet0.34USD tablet
Apo-Trazodone 50 mg Tablet0.23USD tablet
Mylan-Trazodone 50 mg Tablet0.23USD tablet
Novo-Trazodone 50 mg Tablet0.23USD tablet
Nu-Trazodone 50 mg Tablet0.23USD tablet
Pms-Trazodone 50 mg Tablet0.23USD tablet
Ratio-Trazodone 50 mg Tablet0.23USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6607748 No2000-06-292020-06-29Us
US7829120 No2007-03-272027-03-27Us
US8133893 No2009-03-132029-03-13Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point87 °CPhysProp
water solubilitySparigly solubleNot Available
logP2.9Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.29 mg/mLALOGPS
logP2.68ALOGPS
logP3.13ChemAxon
logS-3.1ALOGPS
pKa (Strongest Basic)7.09ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area42.39 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity105.88 m3·mol-1ChemAxon
Polarizability40.12 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0a4i-7980000000-5d2bde624fdd9a946993View in MoNA
References
Synthesis ReferenceNot Available
General References
  1. Marek GJ, McDougle CJ, Price LH, Seiden LS: A comparison of trazodone and fluoxetine: implications for a serotonergic mechanism of antidepressant action. Psychopharmacology (Berl). 1992;109(1-2):2-11. [PubMed:1365657 ]
  2. Jauch R, Kopitar Z, Prox A, Zimmer A: [Pharmacokinetics and metabolism of trazodone in man (author's transl)]. Arzneimittelforschung. 1976;26(11):2084-9. [PubMed:1037253 ]
  3. Rotzinger S, Fang J, Baker GB: Trazodone is metabolized to m-chlorophenylpiperazine by CYP3A4 from human sources. Drug Metab Dispos. 1998 Jun;26(6):572-5. [PubMed:9616194 ]
  4. Kalgutkar AS, Henne KR, Lame ME, Vaz AD, Collin C, Soglia JR, Zhao SX, Hop CE: Metabolic activation of the nontricyclic antidepressant trazodone to electrophilic quinone-imine and epoxide intermediates in human liver microsomes and recombinant P4503A4. Chem Biol Interact. 2005 Jun 30;155(1-2):10-20. Epub 2005 Apr 18. [PubMed:15978881 ]
  5. Otani K, Yasui N, Kaneko S, Ishida M, Ohkubo T, Osanai T, Sugawara K, Fukushima Y: Trazodone treatment increases plasma prolactin concentrations in depressed patients. Int Clin Psychopharmacol. 1995 Jun;10(2):115-7. [PubMed:7673654 ]
  6. Saletu-Zyhlarz GM, Abu-Bakr MH, Anderer P, Gruber G, Mandl M, Strobl R, Gollner D, Prause W, Saletu B: Insomnia in depression: differences in objective and subjective sleep and awakening quality to normal controls and acute effects of trazodone. Prog Neuropsychopharmacol Biol Psychiatry. 2002 Feb;26(2):249-60. [PubMed:11817501 ]
  7. Fink HA, MacDonald R, Rutks IR, Wilt TJ: Trazodone for erectile dysfunction: a systematic review and meta-analysis. BJU Int. 2003 Sep;92(4):441-6. [PubMed:12930437 ]
External Links
ATC CodesN06AX05
AHFS Codes
  • 28:16.04.24
PDB EntriesNot Available
FDA labelDownload (151 KB)
MSDSDownload (73.7 KB)
Interactions
Drug Interactions
Drug
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Trazodone.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the serotonergic activities of Trazodone.
AbirateroneThe metabolism of Trazodone can be decreased when combined with Abiraterone.
AcarboseTrazodone may increase the hypoglycemic activities of Acarbose.
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Trazodone.
AcenocoumarolTrazodone may increase the anticoagulant activities of Acenocoumarol.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Trazodone.
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Trazodone.
AcetaminophenThe serum concentration of Acetaminophen can be decreased when it is combined with Trazodone.
AcetophenazineThe risk or severity of adverse effects can be increased when Trazodone is combined with Acetophenazine.
Acetylsalicylic acidTrazodone may increase the antiplatelet activities of Acetylsalicylic acid.
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Trazodone.
AfatinibThe serum concentration of Afatinib can be decreased when it is combined with Trazodone.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Trazodone.
AlbiglutideTrazodone may increase the hypoglycemic activities of Albiglutide.
AldosteroneThe serum concentration of Aldosterone can be decreased when it is combined with Trazodone.
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Trazodone.
AlfentanilAlfentanil may increase the serotonergic activities of Trazodone.
AlfentanilThe risk or severity of adverse effects can be increased when Trazodone is combined with Alfentanil.
AlimemazineThe risk or severity of adverse effects can be increased when Alimemazine is combined with Trazodone.
AlitretinoinThe serum concentration of Alitretinoin can be decreased when it is combined with Trazodone.
AlmotriptanThe risk or severity of adverse effects can be increased when Trazodone is combined with Almotriptan.
AlogliptinTrazodone may increase the hypoglycemic activities of Alogliptin.
AlphacetylmethadolAlphacetylmethadol may increase the serotonergic activities of Trazodone.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Trazodone is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Trazodone.
AlprenololThe serum concentration of Alprenolol can be increased when it is combined with Trazodone.
AmbrisentanThe serum concentration of Ambrisentan can be decreased when it is combined with Trazodone.
AmiodaroneTrazodone may increase the QTc-prolonging activities of Amiodarone.
AmiodaroneThe metabolism of Trazodone can be decreased when combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Trazodone.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Trazodone.
AmitriptylineThe serum concentration of Amitriptyline can be decreased when it is combined with Trazodone.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Trazodone.
AmoxapineThe risk or severity of adverse effects can be increased when Trazodone is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Trazodone.
AnagrelideTrazodone may increase the QTc-prolonging activities of Anagrelide.
ApixabanThe serum concentration of Apixaban can be decreased when it is combined with Trazodone.
AprepitantThe serum concentration of Trazodone can be increased when it is combined with Aprepitant.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Trazodone.
ArotinololThe serum concentration of Arotinolol can be increased when it is combined with Trazodone.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be decreased when it is combined with Trazodone.
ArtemetherTrazodone may increase the QTc-prolonging activities of Artemether.
ArtemetherThe metabolism of Trazodone can be decreased when combined with Artemether.
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Trazodone.
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Trazodone.
AtazanavirThe serum concentration of Trazodone can be increased when it is combined with Atazanavir.
AtazanavirThe serum concentration of Atazanavir can be decreased when it is combined with Trazodone.
AtenololThe serum concentration of Atenolol can be increased when it is combined with Trazodone.
AtomoxetineThe metabolism of Trazodone can be decreased when combined with Atomoxetine.
AxitinibThe serum concentration of Axitinib can be decreased when it is combined with Trazodone.
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Trazodone.
AzelastineTrazodone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Trazodone.
AzithromycinTrazodone may increase the QTc-prolonging activities of Azithromycin.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Trazodone.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Trazodone.
BedaquilineTrazodone may increase the QTc-prolonging activities of Bedaquiline.
BefunololThe serum concentration of Befunolol can be increased when it is combined with Trazodone.
BendroflumethiazideTrazodone may increase the hyponatremic activities of Bendroflumethiazide.
BenmoxinBenmoxin may increase the serotonergic activities of Trazodone.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Trazodone.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Trazodone.
BetamethasoneThe serum concentration of Betamethasone can be decreased when it is combined with Trazodone.
BetaxololThe serum concentration of Betaxolol can be increased when it is combined with Trazodone.
BetaxololThe metabolism of Trazodone can be decreased when combined with Betaxolol.
BevantololThe serum concentration of Bevantolol can be increased when it is combined with Trazodone.
BexaroteneThe serum concentration of Trazodone can be decreased when it is combined with Bexarotene.
BezitramideBezitramide may increase the serotonergic activities of Trazodone.
BifeprunoxThe risk or severity of adverse effects can be increased when Trazodone is combined with Bifeprunox.
BisoprololThe serum concentration of Bisoprolol can be increased when it is combined with Trazodone.
BoceprevirThe serum concentration of Trazodone can be increased when it is combined with Boceprevir.
BoceprevirThe serum concentration of Boceprevir can be decreased when it is combined with Trazodone.
BopindololThe serum concentration of Bopindolol can be increased when it is combined with Trazodone.
BortezomibThe metabolism of Trazodone can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Trazodone can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Bosutinib can be decreased when it is combined with Trazodone.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Trazodone.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Brexpiprazole is combined with Trazodone.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Trazodone.
BrimonidineThe risk or severity of adverse effects can be increased when Trazodone is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Trazodone.
BromocriptineTrazodone may increase the hypoglycemic activities of Bromocriptine.
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Trazodone.
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Trazodone.
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Trazodone.
BufuralolThe serum concentration of Bufuralol can be increased when it is combined with Trazodone.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Trazodone.
BupranololThe serum concentration of Bupranolol can be increased when it is combined with Trazodone.
BuprenorphineBuprenorphine may increase the serotonergic activities of Trazodone.
BuprenorphineThe risk or severity of adverse effects can be increased when Trazodone is combined with Buprenorphine.
BupropionThe metabolism of Trazodone can be decreased when combined with Bupropion.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Trazodone.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Trazodone.
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Trazodone.
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Trazodone.
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Trazodone.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Trazodone.
ButorphanolButorphanol may increase the serotonergic activities of Trazodone.
ButorphanolThe risk or severity of adverse effects can be increased when Trazodone is combined with Butorphanol.
CabazitaxelThe serum concentration of Cabazitaxel can be decreased when it is combined with Trazodone.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Trazodone.
CaffeineThe serum concentration of Caffeine can be decreased when it is combined with Trazodone.
CamptothecinThe serum concentration of Camptothecin can be decreased when it is combined with Trazodone.
CanagliflozinTrazodone may increase the hypoglycemic activities of Canagliflozin.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Trazodone.
CarbamazepineThe serum concentration of Carbamazepine can be decreased when it is combined with Trazodone.
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Trazodone.
CarfentanilCarfentanil may increase the serotonergic activities of Trazodone.
CarfentanilThe risk or severity of adverse effects can be increased when Trazodone is combined with Carfentanil.
CarfilzomibThe serum concentration of Carfilzomib can be decreased when it is combined with Trazodone.
CariprazineThe risk or severity of adverse effects can be increased when Trazodone is combined with Cariprazine.
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Trazodone.
CaroxazoneCaroxazone may increase the serotonergic activities of Trazodone.
CarteololThe serum concentration of Carteolol can be increased when it is combined with Trazodone.
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Trazodone.
CelecoxibThe metabolism of Trazodone can be decreased when combined with Celecoxib.
CeliprololThe serum concentration of Celiprolol can be increased when it is combined with Trazodone.
CeritinibThe serum concentration of Trazodone can be increased when it is combined with Ceritinib.
CeritinibTrazodone may increase the QTc-prolonging activities of Ceritinib.
CerivastatinThe serum concentration of Cerivastatin can be decreased when it is combined with Trazodone.
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Trazodone.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Trazodone.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Trazodone.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Trazodone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Trazodone.
ChloroquineTrazodone may increase the QTc-prolonging activities of Chloroquine.
ChloroquineThe metabolism of Trazodone can be decreased when combined with Chloroquine.
ChlorothiazideTrazodone may increase the hyponatremic activities of Chlorothiazide.
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Trazodone.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Trazodone.
ChlorpropamideTrazodone may increase the hypoglycemic activities of Chlorpropamide.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Trazodone.
ChlorthalidoneTrazodone may increase the hyponatremic activities of Chlorthalidone.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Trazodone.
CholecalciferolThe metabolism of Trazodone can be decreased when combined with Cholecalciferol.
CimetidineThe serum concentration of Cimetidine can be decreased when it is combined with Trazodone.
CimetidineThe metabolism of Trazodone can be decreased when combined with Cimetidine.
CinacalcetThe metabolism of Trazodone can be decreased when combined with Cinacalcet.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Trazodone.
CiprofloxacinTrazodone may increase the QTc-prolonging activities of Ciprofloxacin.
CisaprideTrazodone may increase the QTc-prolonging activities of Cisapride.
CisplatinThe serum concentration of Cisplatin can be decreased when it is combined with Trazodone.
CitalopramThe risk or severity of adverse effects can be increased when Trazodone is combined with Citalopram.
CitalopramThe metabolism of Trazodone can be decreased when combined with Citalopram.
ClarithromycinTrazodone may increase the QTc-prolonging activities of Clarithromycin.
ClarithromycinThe metabolism of Trazodone can be decreased when combined with Clarithromycin.
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Trazodone.
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Trazodone.
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Trazodone.
ClobazamThe serum concentration of Clobazam can be decreased when it is combined with Trazodone.
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Trazodone.
ClomifeneThe serum concentration of Clomifene can be decreased when it is combined with Trazodone.
ClomipramineThe risk or severity of adverse effects can be increased when Trazodone is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Trazodone.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Trazodone.
ClonidineThe serum concentration of Clonidine can be decreased when it is combined with Trazodone.
ClopidogrelThe serum concentration of Clopidogrel can be decreased when it is combined with Trazodone.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Trazodone.
ClotrimazoleThe metabolism of Trazodone can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Trazodone.
CobicistatThe serum concentration of Trazodone can be increased when it is combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be decreased when it is combined with Trazodone.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Trazodone.
CodeineCodeine may increase the serotonergic activities of Trazodone.
CodeineThe risk or severity of adverse effects can be increased when Trazodone is combined with Codeine.
ColchicineThe serum concentration of Colchicine can be decreased when it is combined with Trazodone.
ConivaptanThe serum concentration of Trazodone can be increased when it is combined with Conivaptan.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Trazodone.
CrizotinibTrazodone may increase the QTc-prolonging activities of Crizotinib.
CrizotinibThe metabolism of Trazodone can be decreased when combined with Crizotinib.
CyamemazineThe risk or severity of adverse effects can be increased when Trazodone is combined with Cyamemazine.
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Trazodone.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Trazodone.
CyclosporineThe metabolism of Trazodone can be decreased when combined with Cyclosporine.
CyclosporineThe serum concentration of Cyclosporine can be decreased when it is combined with Trazodone.
CyproheptadineThe therapeutic efficacy of Trazodone can be decreased when used in combination with Cyproheptadine.
CyproheptadineThe risk or severity of adverse effects can be increased when Trazodone is combined with Cyproheptadine.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Trazodone.
DabrafenibThe serum concentration of Trazodone can be decreased when it is combined with Dabrafenib.
DactinomycinThe serum concentration of Dactinomycin can be decreased when it is combined with Trazodone.
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Trazodone.
DapagliflozinTrazodone may increase the hypoglycemic activities of Dapagliflozin.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Trazodone.
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Trazodone.
DarifenacinThe metabolism of Trazodone can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Trazodone can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Trazodone can be increased when it is combined with Dasatinib.
DasatinibThe serum concentration of Dasatinib can be decreased when it is combined with Trazodone.
DaunorubicinThe serum concentration of Daunorubicin can be decreased when it is combined with Trazodone.
DebrisoquinThe serum concentration of Debrisoquin can be decreased when it is combined with Trazodone.
DeferasiroxThe serum concentration of Trazodone can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Trazodone can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Trazodone.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Trazodone.
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Trazodone.
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Trazodone.
DesmopressinThe risk or severity of adverse effects can be increased when Trazodone is combined with Desmopressin.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Trazodone is combined with Desvenlafaxine.
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Trazodone.
DexamethasoneThe serum concentration of Trazodone can be decreased when it is combined with Dexamethasone.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Trazodone.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Trazodone.
DextromethorphanTrazodone may increase the serotonergic activities of Dextromethorphan.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Trazodone.
DextromoramideDextromoramide may increase the serotonergic activities of Trazodone.
DextromoramideThe risk or severity of adverse effects can be increased when Trazodone is combined with Dextromoramide.
DextropropoxypheneDextropropoxyphene may increase the serotonergic activities of Trazodone.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Trazodone is combined with Dextropropoxyphene.
DezocineDezocine may increase the serotonergic activities of Trazodone.
DezocineThe risk or severity of adverse effects can be increased when Trazodone is combined with Dezocine.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Trazodone.
DiazepamThe serum concentration of Diazepam can be decreased when it is combined with Trazodone.
DicoumarolTrazodone may increase the anticoagulant activities of Dicoumarol.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Trazodone.
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Trazodone.
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with Trazodone.
DigoxinThe serum concentration of Digoxin can be decreased when it is combined with Trazodone.
DihydrocodeineDihydrocodeine may increase the serotonergic activities of Trazodone.
DihydrocodeineThe risk or severity of adverse effects can be increased when Trazodone is combined with Dihydrocodeine.
DihydroergotamineThe metabolism of Trazodone can be decreased when combined with Dihydroergotamine.
DihydroergotamineThe risk or severity of adverse effects can be increased when Trazodone is combined with Dihydroergotamine.
DihydroetorphineDihydroetorphine may increase the serotonergic activities of Trazodone.
DihydroetorphineThe risk or severity of adverse effects can be increased when Trazodone is combined with Dihydroetorphine.
DihydromorphineDihydromorphine may increase the serotonergic activities of Trazodone.
DihydromorphineThe risk or severity of adverse effects can be increased when Trazodone is combined with Dihydromorphine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be decreased when it is combined with Trazodone.
DiltiazemThe metabolism of Trazodone can be decreased when combined with Diltiazem.
DiltiazemThe serum concentration of Diltiazem can be decreased when it is combined with Trazodone.
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Trazodone.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Trazodone.
DiphenoxylateDiphenoxylate may increase the serotonergic activities of Trazodone.
DiphenoxylateThe risk or severity of adverse effects can be increased when Trazodone is combined with Diphenoxylate.
DipyridamoleThe serum concentration of Dipyridamole can be decreased when it is combined with Trazodone.
DisopyramideTrazodone may increase the hypoglycemic activities of Disopyramide.
DocetaxelThe serum concentration of Docetaxel can be decreased when it is combined with Trazodone.
DofetilideTrazodone may increase the QTc-prolonging activities of Dofetilide.
DolasetronTrazodone may increase the QTc-prolonging activities of Dolasetron.
DolasetronDolasetron may increase the serotonergic activities of Trazodone.
DomperidoneThe serum concentration of Domperidone can be decreased when it is combined with Trazodone.
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Trazodone.
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Trazodone.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Trazodone.
DoxorubicinThe serum concentration of Doxorubicin can be decreased when it is combined with Trazodone.
DoxycyclineThe metabolism of Trazodone can be decreased when combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Trazodone.
DoxylamineThe risk or severity of adverse effects can be increased when Trazodone is combined with Doxylamine.
DPDPEDPDPE may increase the serotonergic activities of Trazodone.
DPDPEThe risk or severity of adverse effects can be increased when Trazodone is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Trazodone.
DronedaroneThe metabolism of Trazodone can be decreased when combined with Dronedarone.
DronedaroneTrazodone may increase the QTc-prolonging activities of Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Trazodone.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Trazodone.
DulaglutideTrazodone may increase the hypoglycemic activities of Dulaglutide.
DuloxetineThe metabolism of Trazodone can be decreased when combined with Duloxetine.
DuloxetineThe risk or severity of adverse effects can be increased when Trazodone is combined with Duloxetine.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Trazodone.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Trazodone.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Trazodone.
EdoxabanThe serum concentration of Edoxaban can be decreased when it is combined with Trazodone.
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Trazodone.
EletriptanThe serum concentration of Eletriptan can be decreased when it is combined with Trazodone.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Trazodone.
EliglustatTrazodone may increase the QTc-prolonging activities of Eliglustat.
EliglustatThe metabolism of Trazodone can be decreased when combined with Eliglustat.
EmpagliflozinTrazodone may increase the hypoglycemic activities of Empagliflozin.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Trazodone.
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Trazodone.
EnzalutamideThe serum concentration of Trazodone can be decreased when it is combined with Enzalutamide.
EpinastineThe serum concentration of Epinastine can be decreased when it is combined with Trazodone.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Trazodone is combined with Ergoloid mesylate.
ErgonovineThe risk or severity of adverse effects can be increased when Trazodone is combined with Ergonovine.
ErgotamineThe risk or severity of adverse effects can be increased when Trazodone is combined with Ergotamine.
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Trazodone.
ErythromycinTrazodone may increase the QTc-prolonging activities of Erythromycin.
ErythromycinThe metabolism of Trazodone can be decreased when combined with Erythromycin.
EscitalopramThe risk or severity of adverse effects can be increased when Trazodone is combined with Escitalopram.
EscitalopramEscitalopram may increase the serotonergic activities of Trazodone.
Eslicarbazepine acetateThe serum concentration of Trazodone can be decreased when it is combined with Eslicarbazepine acetate.
EsmololThe serum concentration of Esmolol can be increased when it is combined with Trazodone.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Trazodone.
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Trazodone.
EstriolThe serum concentration of Estriol can be decreased when it is combined with Trazodone.
EstroneThe serum concentration of Estrone can be decreased when it is combined with Trazodone.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Trazodone.
EthanolTrazodone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Trazodone.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Trazodone.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Trazodone.
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Trazodone.
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Trazodone.
Ethyl biscoumacetateTrazodone may increase the anticoagulant activities of Ethyl biscoumacetate.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Trazodone.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Trazodone.
EthylmorphineEthylmorphine may increase the serotonergic activities of Trazodone.
EthylmorphineThe risk or severity of adverse effects can be increased when Trazodone is combined with Ethylmorphine.
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Trazodone.
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Trazodone.
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Trazodone.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Trazodone.
EtoperidoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Etoperidone.
EtoperidoneEtoperidone may increase the serotonergic activities of Trazodone.
EtoposideThe serum concentration of Etoposide can be decreased when it is combined with Trazodone.
EtorphineEtorphine may increase the serotonergic activities of Trazodone.
EtorphineThe risk or severity of adverse effects can be increased when Trazodone is combined with Etorphine.
EtravirineThe serum concentration of Trazodone can be decreased when it is combined with Etravirine.
ExenatideTrazodone may increase the hypoglycemic activities of Exenatide.
EzetimibeThe serum concentration of Ezetimibe can be decreased when it is combined with Trazodone.
EzogabineThe risk or severity of adverse effects can be increased when Ezogabine is combined with Trazodone.
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Trazodone.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Trazodone.
FenfluramineThe risk or severity of adverse effects can be increased when Trazodone is combined with Fenfluramine.
FenfluramineFenfluramine may increase the serotonergic activities of Trazodone.
FentanylFentanyl may increase the serotonergic activities of Trazodone.
FentanylThe risk or severity of adverse effects can be increased when Trazodone is combined with Fentanyl.
FesoterodineThe serum concentration of Fesoterodine can be decreased when it is combined with Trazodone.
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Trazodone.
FexofenadineThe serum concentration of Fexofenadine can be decreased when it is combined with Trazodone.
FidaxomicinThe serum concentration of Fidaxomicin can be decreased when it is combined with Trazodone.
FlecainideTrazodone may increase the QTc-prolonging activities of Flecainide.
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Trazodone.
FluconazoleThe metabolism of Trazodone can be decreased when combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Trazodone.
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Trazodone.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Trazodone.
FluoxetineThe risk or severity of adverse effects can be increased when Trazodone is combined with Fluoxetine.
FluoxetineFluoxetine may increase the serotonergic activities of Trazodone.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Trazodone.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Trazodone.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Trazodone.
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Trazodone.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be decreased when it is combined with Trazodone.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Trazodone.
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Trazodone.
FosamprenavirThe metabolism of Trazodone can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Trazodone can be increased when it is combined with Fosaprepitant.
FosphenytoinThe serum concentration of Trazodone can be decreased when it is combined with Fosphenytoin.
FosphenytoinThe risk or severity of adverse effects can be increased when Trazodone is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Trazodone.
FrovatriptanThe risk or severity of adverse effects can be increased when Trazodone is combined with Frovatriptan.
FurazolidoneFurazolidone may increase the serotonergic activities of Trazodone.
Fusidic AcidThe serum concentration of Trazodone can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Trazodone.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when gabapentin enacarbil is combined with Trazodone.
Gadobenic acidTrazodone may increase the QTc-prolonging activities of Gadobenic acid.
GalantamineThe metabolism of Galantamine can be decreased when combined with Trazodone.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Trazodone.
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Trazodone.
GemcitabineThe serum concentration of Gemcitabine can be decreased when it is combined with Trazodone.
GemifloxacinTrazodone may increase the QTc-prolonging activities of Gemifloxacin.
GliclazideTrazodone may increase the hypoglycemic activities of Gliclazide.
GlimepirideTrazodone may increase the hypoglycemic activities of Glimepiride.
GlipizideTrazodone may increase the hypoglycemic activities of Glipizide.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Trazodone.
GlyburideTrazodone may increase the hypoglycemic activities of Glyburide.
GoserelinTrazodone may increase the QTc-prolonging activities of Goserelin.
GranisetronTrazodone may increase the QTc-prolonging activities of Granisetron.
GranisetronGranisetron may increase the serotonergic activities of Trazodone.
GrazoprevirThe serum concentration of Grazoprevir can be decreased when it is combined with Trazodone.
GrepafloxacinThe serum concentration of Grepafloxacin can be decreased when it is combined with Trazodone.
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Trazodone.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Trazodone.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Trazodone.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Trazodone.
HeroinHeroin may increase the serotonergic activities of Trazodone.
HeroinThe risk or severity of adverse effects can be increased when Trazodone is combined with Heroin.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Trazodone.
HydracarbazineHydracarbazine may increase the serotonergic activities of Trazodone.
HydrochlorothiazideTrazodone may increase the hyponatremic activities of Hydrochlorothiazide.
HydrocodoneHydrocodone may increase the serotonergic activities of Trazodone.
HydrocodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Hydrocodone.
HydrocortisoneThe serum concentration of Hydrocortisone can be decreased when it is combined with Trazodone.
HydroflumethiazideTrazodone may increase the hyponatremic activities of Hydroflumethiazide.
HydromorphoneHydromorphone may increase the serotonergic activities of Trazodone.
HydromorphoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Hydromorphone.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Trazodone.
HydroxyzineThe risk or severity of adverse effects can be increased when Trazodone is combined with Hydroxyzine.
IbuprofenThe serum concentration of Ibuprofen can be decreased when it is combined with Trazodone.
IbutilideTrazodone may increase the QTc-prolonging activities of Ibutilide.
IdelalisibThe serum concentration of Trazodone can be increased when it is combined with Idelalisib.
IdelalisibThe serum concentration of Idelalisib can be decreased when it is combined with Trazodone.
IloperidoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Trazodone.
ImatinibThe metabolism of Trazodone can be decreased when combined with Imatinib.
ImatinibThe serum concentration of Imatinib can be decreased when it is combined with Trazodone.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Trazodone.
ImipramineThe serum concentration of Imipramine can be decreased when it is combined with Trazodone.
IndacaterolThe serum concentration of Indacaterol can be decreased when it is combined with Trazodone.
IndalpineThe risk or severity of adverse effects can be increased when Trazodone is combined with Indalpine.
IndalpineIndalpine may increase the serotonergic activities of Trazodone.
IndapamideTrazodone may increase the hyponatremic activities of Indapamide.
IndenololThe serum concentration of Indenolol can be increased when it is combined with Trazodone.
IndinavirThe serum concentration of Indinavir can be decreased when it is combined with Trazodone.
IndinavirThe metabolism of Trazodone can be decreased when combined with Indinavir.
IndomethacinThe serum concentration of Indomethacin can be decreased when it is combined with Trazodone.
Insulin AspartTrazodone may increase the hypoglycemic activities of Insulin Aspart.
Insulin DetemirTrazodone may increase the hypoglycemic activities of Insulin Detemir.
Insulin GlargineTrazodone may increase the hypoglycemic activities of Insulin Glargine.
Insulin GlulisineTrazodone may increase the hypoglycemic activities of Insulin Glulisine.
Insulin HumanTrazodone may increase the hypoglycemic activities of Insulin Human.
Insulin LisproTrazodone may increase the hypoglycemic activities of Insulin Lispro.
Ioflupane I-123Trazodone may decrease effectiveness of Ioflupane I 123 as a diagnostic agent.
IproclozideIproclozide may increase the serotonergic activities of Trazodone.
IproniazidIproniazid may increase the serotonergic activities of Trazodone.
IrinotecanThe serum concentration of Irinotecan can be decreased when it is combined with Trazodone.
IsavuconazoniumThe metabolism of Trazodone can be decreased when combined with Isavuconazonium.
IsocarboxazidIsocarboxazid may increase the serotonergic activities of Trazodone.
IsocarboxazidThe risk or severity of adverse effects can be increased when Trazodone is combined with Isocarboxazid.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Trazodone.
IsoniazidThe metabolism of Trazodone can be decreased when combined with Isoniazid.
IsradipineThe metabolism of Trazodone can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Trazodone can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Trazodone can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Ivermectin can be decreased when it is combined with Trazodone.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Trazodone.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Trazodone.
KetazolamThe serum concentration of Ketazolam can be decreased when it is combined with Trazodone.
KetobemidoneKetobemidone may increase the serotonergic activities of Trazodone.
KetobemidoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Ketobemidone.
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Trazodone.
KetoconazoleThe metabolism of Trazodone can be decreased when combined with Ketoconazole.
L-TryptophanL-Tryptophan may increase the serotonergic activities of Trazodone.
LabetalolThe serum concentration of Labetalol can be increased when it is combined with Trazodone.
LamivudineThe serum concentration of Lamivudine can be decreased when it is combined with Trazodone.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Trazodone.
LamotrigineThe serum concentration of Lamotrigine can be decreased when it is combined with Trazodone.
LanreotideTrazodone may increase the hypoglycemic activities of Lanreotide.
LansoprazoleThe serum concentration of Lansoprazole can be decreased when it is combined with Trazodone.
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Trazodone.
LenalidomideThe serum concentration of Lenalidomide can be decreased when it is combined with Trazodone.
LenvatinibTrazodone may increase the QTc-prolonging activities of Lenvatinib.
LeuprolideTrazodone may increase the QTc-prolonging activities of Leuprolide.
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Trazodone.
LevetiracetamThe serum concentration of Levetiracetam can be decreased when it is combined with Trazodone.
LevobunololThe serum concentration of Levobunolol can be increased when it is combined with Trazodone.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Trazodone.
LevocabastineThe risk or severity of adverse effects can be increased when Levocabastine is combined with Trazodone.
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Trazodone.
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Trazodone.
LevofloxacinTrazodone may increase the QTc-prolonging activities of Levofloxacin.
Levomethadyl AcetateLevomethadyl Acetate may increase the serotonergic activities of Trazodone.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Trazodone is combined with Levomethadyl Acetate.
LevomilnacipranThe risk or severity of adverse effects can be increased when Trazodone is combined with Levomilnacipran.
LevomilnacipranLevomilnacipran may increase the serotonergic activities of Trazodone.
LevorphanolLevorphanol may increase the serotonergic activities of Trazodone.
LevorphanolThe risk or severity of adverse effects can be increased when Trazodone is combined with Levorphanol.
LevothyroxineThe therapeutic efficacy of Levothyroxine can be decreased when used in combination with Trazodone.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Trazodone.
LinagliptinThe serum concentration of Linagliptin can be decreased when it is combined with Trazodone.
LinezolidLinezolid may increase the serotonergic activities of Trazodone.
LinezolidThe risk or severity of adverse effects can be increased when Trazodone is combined with Linezolid.
LiothyronineThe therapeutic efficacy of Liothyronine can be decreased when used in combination with Trazodone.
LiotrixThe therapeutic efficacy of Liotrix can be decreased when used in combination with Trazodone.
LiraglutideTrazodone may increase the hypoglycemic activities of Liraglutide.
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Trazodone.
LofentanilLofentanil may increase the serotonergic activities of Trazodone.
LofentanilThe risk or severity of adverse effects can be increased when Trazodone is combined with Lofentanil.
LoperamideThe serum concentration of Loperamide can be decreased when it is combined with Trazodone.
LopinavirLopinavir may increase the QTc-prolonging activities of Trazodone.
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Trazodone.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Trazodone.
LorcaserinThe metabolism of Trazodone can be decreased when combined with Lorcaserin.
LorcaserinThe risk or severity of adverse effects can be increased when Trazodone is combined with Lorcaserin.
LosartanThe serum concentration of Losartan can be decreased when it is combined with Trazodone.
LovastatinThe metabolism of Trazodone can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Trazodone.
Lu AA21004The risk or severity of adverse effects can be increased when Trazodone is combined with Lu AA21004.
LuliconazoleThe serum concentration of Trazodone can be increased when it is combined with Luliconazole.
LumefantrineTrazodone may increase the QTc-prolonging activities of Lumefantrine.
LumefantrineThe metabolism of Trazodone can be decreased when combined with Lumefantrine.
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Trazodone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Trazodone.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Trazodone is combined with Magnesium Sulfate.
MannitolThe serum concentration of Mannitol can be decreased when it is combined with Trazodone.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Trazodone.
MebanazineMebanazine may increase the serotonergic activities of Trazodone.
MecaserminTrazodone may increase the hypoglycemic activities of Mecasermin.
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Trazodone.
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Trazodone.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Trazodone.
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Trazodone.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Trazodone.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Trazodone.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Trazodone.
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Trazodone.
MetforminTrazodone may increase the hypoglycemic activities of Metformin.
MethadoneMethadone may increase the serotonergic activities of Trazodone.
MethadoneTrazodone may increase the QTc-prolonging activities of Methadone.
Methadyl AcetateMethadyl Acetate may increase the serotonergic activities of Trazodone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Trazodone is combined with Methadyl Acetate.
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Trazodone.
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Trazodone.
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Trazodone.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Trazodone.
MethotrexateThe serum concentration of Methotrexate can be decreased when it is combined with Trazodone.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Trazodone.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Trazodone.
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Trazodone.
MethyclothiazideTrazodone may increase the hyponatremic activities of Methyclothiazide.
Methylene blueTrazodone may increase the serotonergic activities of Methylene blue.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Trazodone.
MethylprednisoloneThe serum concentration of Methylprednisolone can be decreased when it is combined with Trazodone.
MetipranololThe serum concentration of Metipranolol can be increased when it is combined with Trazodone.
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Trazodone.
MetolazoneTrazodone may increase the hyponatremic activities of Metolazone.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Trazodone.
MetoprololThe metabolism of Trazodone can be decreased when combined with Metoprolol.
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Trazodone.
MetyrosineTrazodone may increase the sedative activities of Metyrosine.
MexiletineThe metabolism of Mexiletine can be decreased when combined with Trazodone.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Trazodone.
MidazolamThe serum concentration of Midazolam can be decreased when it is combined with Trazodone.
MifepristoneTrazodone may increase the hypoglycemic activities of Mifepristone.
MifepristoneThe metabolism of Trazodone can be decreased when combined with Mifepristone.
MiglitolTrazodone may increase the hypoglycemic activities of Miglitol.
MilnacipranThe risk or severity of adverse effects can be increased when Trazodone is combined with Milnacipran.
MilnacipranMilnacipran may increase the serotonergic activities of Trazodone.
MinaprineMinaprine may increase the serotonergic activities of Trazodone.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Trazodone.
MirabegronThe serum concentration of Mirabegron can be decreased when it is combined with Trazodone.
MirabegronThe metabolism of Trazodone can be decreased when combined with Mirabegron.
MirtazapineTrazodone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Trazodone.
MitotaneThe serum concentration of Trazodone can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Mitoxantrone can be decreased when it is combined with Trazodone.
MoclobemideMoclobemide may increase the serotonergic activities of Trazodone.
MoclobemideThe risk or severity of adverse effects can be increased when Trazodone is combined with Moclobemide.
ModafinilThe serum concentration of Trazodone can be decreased when it is combined with Modafinil.
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Trazodone.
MoricizineThe risk or severity of adverse effects can be increased when Moricizine is combined with Trazodone.
MorphineMorphine may increase the serotonergic activities of Trazodone.
MorphineThe serum concentration of Morphine can be decreased when it is combined with Trazodone.
MoxifloxacinTrazodone may increase the QTc-prolonging activities of Moxifloxacin.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Trazodone.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Trazodone.
NabiloneThe risk or severity of adverse effects can be increased when Trazodone is combined with Nabilone.
NadololThe serum concentration of Nadolol can be increased when it is combined with Trazodone.
NafcillinThe serum concentration of Trazodone can be decreased when it is combined with Nafcillin.
NalbuphineNalbuphine may increase the serotonergic activities of Trazodone.
NalbuphineThe risk or severity of adverse effects can be increased when Trazodone is combined with Nalbuphine.
NaloxoneThe serum concentration of Naloxone can be decreased when it is combined with Trazodone.
NaratriptanThe risk or severity of adverse effects can be increased when Trazodone is combined with Naratriptan.
NateglinideTrazodone may increase the hypoglycemic activities of Nateglinide.
NefazodoneThe metabolism of Trazodone can be decreased when combined with Nefazodone.
NefazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Nefazodone.
NelfinavirThe serum concentration of Trazodone can be increased when it is combined with Nelfinavir.
NelfinavirThe serum concentration of Nelfinavir can be decreased when it is combined with Trazodone.
NetupitantThe serum concentration of Trazodone can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Trazodone can be decreased when combined with Nevirapine.
NialamideNialamide may increase the serotonergic activities of Trazodone.
NicardipineThe serum concentration of Nicardipine can be decreased when it is combined with Trazodone.
NicardipineThe metabolism of Trazodone can be decreased when combined with Nicardipine.
NifedipineThe serum concentration of Nifedipine can be decreased when it is combined with Trazodone.
NilotinibThe metabolism of Trazodone can be decreased when combined with Nilotinib.
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Trazodone.
NintedanibThe serum concentration of Nintedanib can be decreased when it is combined with Trazodone.
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Trazodone.
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Trazodone.
NizatidineThe serum concentration of Nizatidine can be decreased when it is combined with Trazodone.
NormethadoneNormethadone may increase the serotonergic activities of Trazodone.
NormethadoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Trazodone.
OctamoxinOctamoxin may increase the serotonergic activities of Trazodone.
OctreotideTrazodone may increase the hypoglycemic activities of Octreotide.
OfloxacinTrazodone may increase the QTc-prolonging activities of Ofloxacin.
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Trazodone.
OlaparibThe metabolism of Trazodone can be decreased when combined with Olaparib.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Trazodone.
OmbitasvirThe serum concentration of Ombitasvir can be decreased when it is combined with Trazodone.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Trazodone.
OpiumOpium may increase the serotonergic activities of Trazodone.
OpiumThe risk or severity of adverse effects can be increased when Trazodone is combined with Opium.
OrphenadrineTrazodone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Trazodone.
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Trazodone.
OsimertinibThe serum concentration of Trazodone can be increased when it is combined with Osimertinib.
OsimertinibThe serum concentration of Osimertinib can be decreased when it is combined with Trazodone.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Trazodone.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Trazodone.
OxprenololThe serum concentration of Oxprenolol can be increased when it is combined with Trazodone.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Trazodone.
OxycodoneOxycodone may increase the serotonergic activities of Trazodone.
OxycodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Oxycodone.
OxymorphoneOxymorphone may increase the serotonergic activities of Trazodone.
OxymorphoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Oxymorphone.
PaclitaxelThe serum concentration of Paclitaxel can be decreased when it is combined with Trazodone.
PalbociclibThe serum concentration of Trazodone can be increased when it is combined with Palbociclib.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Trazodone.
PalonosetronPalonosetron may increase the serotonergic activities of Trazodone.
PanobinostatTrazodone may increase the QTc-prolonging activities of Panobinostat.
PanobinostatThe metabolism of Trazodone can be decreased when combined with Panobinostat.
ParaldehydeTrazodone may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Trazodone.
PargylinePargyline may increase the serotonergic activities of Trazodone.
ParoxetineThe risk or severity of adverse effects can be increased when Trazodone is combined with Paroxetine.
ParoxetineParoxetine may increase the serotonergic activities of Trazodone.
PasireotideTrazodone may increase the hypoglycemic activities of Pasireotide.
PazopanibTrazodone may increase the QTc-prolonging activities of Pazopanib.
Peginterferon alfa-2bThe serum concentration of Trazodone can be decreased when it is combined with Peginterferon alfa-2b.
PenbutololThe serum concentration of Penbutolol can be increased when it is combined with Trazodone.
PentamidineTrazodone may increase the hypoglycemic activities of Pentamidine.
PentazocinePentazocine may increase the serotonergic activities of Trazodone.
PentazocineThe risk or severity of adverse effects can be increased when Trazodone is combined with Pentazocine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Trazodone.
PerampanelThe risk or severity of adverse effects can be increased when Perampanel is combined with Trazodone.
PerflutrenTrazodone may increase the QTc-prolonging activities of Perflutren.
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Trazodone.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Trazodone.
PethidinePethidine may increase the serotonergic activities of Trazodone.
PethidineThe risk or severity of adverse effects can be increased when Trazodone is combined with Pethidine.
PhenelzinePhenelzine may increase the serotonergic activities of Trazodone.
PhenelzineThe risk or severity of adverse effects can be increased when Trazodone is combined with Phenelzine.
PhenindioneTrazodone may increase the anticoagulant activities of Phenindione.
PheniprazinePheniprazine may increase the serotonergic activities of Trazodone.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Trazodone.
PhenobarbitalThe serum concentration of Phenobarbital can be decreased when it is combined with Trazodone.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Trazodone.
PhenoxypropazinePhenoxypropazine may increase the serotonergic activities of Trazodone.
PhenprocoumonTrazodone may increase the anticoagulant activities of Phenprocoumon.
PhenytoinThe serum concentration of Trazodone can be decreased when it is combined with Phenytoin.
PimozideThe risk or severity of adverse effects can be increased when Trazodone is combined with Pimozide.
PindololThe serum concentration of Pindolol can be increased when it is combined with Trazodone.
PioglitazoneTrazodone may increase the hypoglycemic activities of Pioglitazone.
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Trazodone.
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Trazodone.
PirlindolePirlindole may increase the serotonergic activities of Trazodone.
PitavastatinThe serum concentration of Pitavastatin can be decreased when it is combined with Trazodone.
PivhydrazinePivhydrazine may increase the serotonergic activities of Trazodone.
PizotifenThe risk or severity of adverse effects can be increased when Pizotifen is combined with Trazodone.
PolythiazideTrazodone may increase the hyponatremic activities of Polythiazide.
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Trazodone.
PomalidomideThe serum concentration of Pomalidomide can be decreased when it is combined with Trazodone.
PonatinibThe serum concentration of Ponatinib can be decreased when it is combined with Trazodone.
PosaconazoleThe metabolism of Trazodone can be decreased when combined with Posaconazole.
PractololThe serum concentration of Practolol can be increased when it is combined with Trazodone.
PramipexoleTrazodone may increase the sedative activities of Pramipexole.
PramlintideTrazodone may increase the hypoglycemic activities of Pramlintide.
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Trazodone.
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Trazodone.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Trazodone.
PrazosinThe serum concentration of Prazosin can be decreased when it is combined with Trazodone.
PrednisoloneThe serum concentration of Prednisolone can be decreased when it is combined with Trazodone.
PrednisoneThe serum concentration of Prednisone can be decreased when it is combined with Trazodone.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Trazodone.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Trazodone.
PrimaquineTrazodone may increase the QTc-prolonging activities of Primaquine.
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Trazodone.
ProcainamideTrazodone may increase the QTc-prolonging activities of Procainamide.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Trazodone.
ProcarbazineThe risk or severity of adverse effects can be increased when Trazodone is combined with Procarbazine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Trazodone.
ProgesteroneThe serum concentration of Progesterone can be decreased when it is combined with Trazodone.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Trazodone.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Trazodone.
PropafenoneTrazodone may increase the QTc-prolonging activities of Propafenone.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Trazodone.
PropericiazineThe risk or severity of adverse effects can be increased when Trazodone is combined with Propericiazine.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Trazodone.
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Trazodone.
PropranololThe serum concentration of Propranolol can be increased when it is combined with Trazodone.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Trazodone.
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Trazodone.
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Trazodone.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Trazodone.
QuinethazoneTrazodone may increase the hyponatremic activities of Quinethazone.
QuinidineThe serum concentration of Quinidine can be decreased when it is combined with Trazodone.
QuinidineThe metabolism of Trazodone can be decreased when combined with Quinidine.
QuinineTrazodone may increase the hypoglycemic activities of Quinine.
QuinineThe metabolism of Trazodone can be decreased when combined with Quinine.
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Trazodone.
RanitidineThe serum concentration of Ranitidine can be decreased when it is combined with Trazodone.
RanolazineThe metabolism of Trazodone can be decreased when combined with Ranolazine.
RasagilineRasagiline may increase the serotonergic activities of Trazodone.
RasagilineThe risk or severity of adverse effects can be increased when Trazodone is combined with Rasagiline.
RemifentanilRemifentanil may increase the serotonergic activities of Trazodone.
RemifentanilThe risk or severity of adverse effects can be increased when Trazodone is combined with Remifentanil.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Trazodone.
RepaglinideTrazodone may increase the hypoglycemic activities of Repaglinide.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Trazodone.
RifabutinThe metabolism of Trazodone can be increased when combined with Rifabutin.
RifampicinThe metabolism of Trazodone can be increased when combined with Rifampicin.
RifampicinThe serum concentration of Rifampicin can be decreased when it is combined with Trazodone.
RifapentineThe metabolism of Trazodone can be increased when combined with Rifapentine.
RisperidoneThe metabolism of Risperidone can be decreased when combined with Trazodone.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Trazodone.
RitonavirThe serum concentration of Trazodone can be increased when it is combined with Ritonavir.
RitonavirThe serum concentration of Ritonavir can be decreased when it is combined with Trazodone.
RivaroxabanThe serum concentration of Rivaroxaban can be decreased when it is combined with Trazodone.
RizatriptanThe risk or severity of adverse effects can be increased when Trazodone is combined with Rizatriptan.
RolapitantThe metabolism of Trazodone can be decreased when combined with Rolapitant.
RomidepsinThe serum concentration of Romidepsin can be decreased when it is combined with Trazodone.
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Trazodone.
RopiniroleTrazodone may increase the sedative activities of Ropinirole.
RopiniroleThe metabolism of Trazodone can be decreased when combined with Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Trazodone.
RosiglitazoneTrazodone may increase the hypoglycemic activities of Rosiglitazone.
RotigotineTrazodone may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Trazodone.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Trazodone.
SafrazineSafrazine may increase the serotonergic activities of Trazodone.
Salicylic acidThe serum concentration of Salicylic acid can be decreased when it is combined with Trazodone.
SaquinavirSaquinavir may increase the QTc-prolonging activities of Trazodone.
SaxagliptinTrazodone may increase the hypoglycemic activities of Saxagliptin.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Trazodone.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Trazodone.
SelegilineSelegiline may increase the serotonergic activities of Trazodone.
SelegilineThe risk or severity of adverse effects can be increased when Trazodone is combined with Selegiline.
SelexipagThe serum concentration of Selexipag can be decreased when it is combined with Trazodone.
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Trazodone.
SertralineThe risk or severity of adverse effects can be increased when Trazodone is combined with Sertraline.
SertralineThe metabolism of Trazodone can be decreased when combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Trazodone.
SildenafilThe metabolism of Trazodone can be decreased when combined with Sildenafil.
SilodosinThe serum concentration of Silodosin can be decreased when it is combined with Trazodone.
SiltuximabThe serum concentration of Trazodone can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Trazodone can be increased when it is combined with Simeprevir.
SimeprevirThe serum concentration of Simeprevir can be decreased when it is combined with Trazodone.
SitagliptinTrazodone may increase the hypoglycemic activities of Sitagliptin.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Trazodone.
SofosbuvirThe serum concentration of Sofosbuvir can be decreased when it is combined with Trazodone.
SorafenibThe serum concentration of Sorafenib can be decreased when it is combined with Trazodone.
SotalolThe serum concentration of Sotalol can be increased when it is combined with Trazodone.
SparfloxacinThe serum concentration of Sparfloxacin can be decreased when it is combined with Trazodone.
SphingosineThe serum concentration of Sphingosine can be decreased when it is combined with Trazodone.
St. John's WortThe serum concentration of Trazodone can be decreased when it is combined with St. John's Wort.
StiripentolThe risk or severity of adverse effects can be increased when Stiripentol is combined with Trazodone.
SufentanilSufentanil may increase the serotonergic activities of Trazodone.
SufentanilThe risk or severity of adverse effects can be increased when Trazodone is combined with Sufentanil.
SulfadiazineTrazodone may increase the hypoglycemic activities of Sulfadiazine.
SulfamethoxazoleTrazodone may increase the hypoglycemic activities of Sulfamethoxazole.
SulfisoxazoleTrazodone may increase the hypoglycemic activities of Sulfisoxazole.
SulfisoxazoleThe metabolism of Trazodone can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Trazodone.
SumatriptanThe risk or severity of adverse effects can be increased when Trazodone is combined with Sumatriptan.
SunitinibTrazodone may increase the hypoglycemic activities of Sunitinib.
SuvorexantThe risk or severity of adverse effects can be increased when Suvorexant is combined with Trazodone.
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Trazodone.
TamoxifenThe serum concentration of Tamoxifen can be decreased when it is combined with Trazodone.
TapentadolTapentadol may increase the serotonergic activities of Trazodone.
TapentadolThe risk or severity of adverse effects can be increased when Trazodone is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Tasimelteon is combined with Trazodone.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be decreased when it is combined with Trazodone.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be decreased when it is combined with Trazodone.
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Trazodone.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Trazodone is combined with Tedizolid Phosphate.
TelaprevirThe serum concentration of Trazodone can be increased when it is combined with Telaprevir.
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Trazodone.
TelavancinTrazodone may increase the QTc-prolonging activities of Telavancin.
TelithromycinTrazodone may increase the QTc-prolonging activities of Telithromycin.
TelithromycinThe metabolism of Trazodone can be decreased when combined with Telithromycin.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Trazodone.
TemsirolimusThe serum concentration of Temsirolimus can be decreased when it is combined with Trazodone.
TerbinafineThe metabolism of Trazodone can be decreased when combined with Terbinafine.
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Trazodone.
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Trazodone.
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Trazodone.
ThalidomideTrazodone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Trazodone.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Trazodone.
ThiethylperazineThe risk or severity of adverse effects can be increased when Thiethylperazine is combined with Trazodone.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Trazodone.
ThioproperazineThe risk or severity of adverse effects can be increased when Trazodone is combined with Thioproperazine.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Trazodone.
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Trazodone.
Thyroid, porcineThe therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Trazodone.
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Trazodone.
TicagrelorThe serum concentration of Ticagrelor can be decreased when it is combined with Trazodone.
TiclopidineThe metabolism of Trazodone can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Trazodone.
TimololThe serum concentration of Timolol can be increased when it is combined with Trazodone.
TipranavirThe serum concentration of Trazodone can be increased when it is combined with Tipranavir.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Trazodone.
TocilizumabThe serum concentration of Trazodone can be decreased when it is combined with Tocilizumab.
TolazamideTrazodone may increase the hypoglycemic activities of Tolazamide.
TolbutamideTrazodone may increase the hypoglycemic activities of Tolbutamide.
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Trazodone.
ToloxatoneToloxatone may increase the serotonergic activities of Trazodone.
TolvaptanThe serum concentration of Tolvaptan can be decreased when it is combined with Trazodone.
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Trazodone.
TopotecanThe serum concentration of Topotecan can be decreased when it is combined with Trazodone.
ToremifeneThe serum concentration of Toremifene can be decreased when it is combined with Trazodone.
TramadolTramadol may increase the serotonergic activities of Trazodone.
TramadolThe risk or severity of adverse effects can be increased when Trazodone is combined with Tramadol.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Trazodone.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trazodone is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineTranylcypromine may increase the serotonergic activities of Trazodone.
TranylcypromineThe risk or severity of adverse effects can be increased when Trazodone is combined with Tranylcypromine.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be decreased when it is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Trazodone.
TrichlormethiazideTrazodone may increase the hyponatremic activities of Trichlormethiazide.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Trazodone.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Trazodone.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Trazodone.
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Trazodone.
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Trazodone.
UmeclidiniumThe serum concentration of Umeclidinium can be decreased when it is combined with Trazodone.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Trazodone.
VandetanibTrazodone may increase the QTc-prolonging activities of Vandetanib.
VecuroniumThe serum concentration of Vecuronium can be decreased when it is combined with Trazodone.
VemurafenibTrazodone may increase the QTc-prolonging activities of Vemurafenib.
VenlafaxineThe metabolism of Trazodone can be decreased when combined with Venlafaxine.
VenlafaxineThe serum concentration of Venlafaxine can be decreased when it is combined with Trazodone.
VerapamilThe metabolism of Trazodone can be decreased when combined with Verapamil.
VerapamilThe serum concentration of Verapamil can be decreased when it is combined with Trazodone.
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Trazodone.
VilazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Vilazodone.
VilazodoneVilazodone may increase the serotonergic activities of Trazodone.
VinblastineThe serum concentration of Vinblastine can be decreased when it is combined with Trazodone.
VincristineThe serum concentration of Vincristine can be decreased when it is combined with Trazodone.
VismodegibThe serum concentration of Vismodegib can be decreased when it is combined with Trazodone.
VoriconazoleThe metabolism of Trazodone can be decreased when combined with Voriconazole.
VortioxetineThe risk or severity of adverse effects can be increased when Trazodone is combined with Vortioxetine.
WarfarinTrazodone may decrease the anticoagulant activities of Warfarin.
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Trazodone.
YohimbineThe therapeutic efficacy of Trazodone can be decreased when used in combination with Yohimbine.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Trazodone.
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Trazodone.
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Trazodone.
ZimelidineThe risk or severity of adverse effects can be increased when Trazodone is combined with Zimelidine.
ZimelidineZimelidine may increase the serotonergic activities of Trazodone.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Trazodone.
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Trazodone.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Trazodone.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Trazodone.
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Trazodone.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Trazodone.
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Trazodone.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Trazodone.
Food Interactions
  • Avoid alcohol.
  • Food decreases the rate and extent of absorption.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Pazzagli M, Giovannini MG, Pepeu G: Trazodone increases extracellular serotonin levels in the frontal cortex of rats. Eur J Pharmacol. 1999 Nov 3;383(3):249-57. [PubMed:10594316 ]
  2. Marcoli M, Rosu C, Bonfanti A, Raiteri M, Maura G: Inhibitory presynaptic 5-hydroxytryptamine(2A) receptors regulate evoked glutamate release from rat cerebellar mossy fibers. J Pharmacol Exp Ther. 2001 Dec;299(3):1106-11. [PubMed:11714900 ]
  3. Marek GJ, McDougle CJ, Price LH, Seiden LS: A comparison of trazodone and fluoxetine: implications for a serotonergic mechanism of antidepressant action. Psychopharmacology (Berl). 1992;109(1-2):2-11. [PubMed:1365657 ]
  4. Luparini MR, Garrone B, Pazzagli M, Pinza M, Pepeu G: A cortical GABA-5HT interaction in the mechanism of action of the antidepressant trazodone. Prog Neuropsychopharmacol Biol Psychiatry. 2004 Nov;28(7):1117-27. [PubMed:15610924 ]
  5. Conn PJ, Sanders-Bush E: Relative efficacies of piperazines at the phosphoinositide hydrolysis-linked serotonergic (5-HT-2 and 5-HT-1c) receptors. J Pharmacol Exp Ther. 1987 Aug;242(2):552-7. [PubMed:3039120 ]
  6. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modul...
Gene Name:
HTR2C
Uniprot ID:
P28335
Molecular Weight:
51820.705 Da
References
  1. Fiorella D, Rabin RA, Winter JC: The role of the 5-HT2A and 5-HT2C receptors in the stimulus effects of m-chlorophenylpiperazine. Psychopharmacology (Berl). 1995 May;119(2):222-30. [PubMed:7659770 ]
  2. Conn PJ, Sanders-Bush E: Relative efficacies of piperazines at the phosphoinositide hydrolysis-linked serotonergic (5-HT-2 and 5-HT-1c) receptors. J Pharmacol Exp Ther. 1987 Aug;242(2):552-7. [PubMed:3039120 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Serotonin:sodium symporter activity
Specific Function:
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin an...
Gene Name:
SLC6A4
Uniprot ID:
P31645
Molecular Weight:
70324.165 Da
References
  1. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
partial agonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G pro...
Gene Name:
HTR1A
Uniprot ID:
P08908
Molecular Weight:
46106.335 Da
References
  1. Odagaki Y, Toyoshima R, Yamauchi T: Trazodone and its active metabolite m-chlorophenylpiperazine as partial agonists at 5-HT1A receptors assessed by [35S]GTPgammaS binding. J Psychopharmacol. 2005 May;19(3):235-41. [PubMed:15888508 ]
  2. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
  3. Subhash MN, Srinivas BN, Vinod KY: Alterations in 5-HT(1A) receptors and adenylyl cyclase response by trazodone in regions of rat brain. Life Sci. 2002 Aug 16;71(13):1559-67. [PubMed:12127910 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
Gene Name:
HRH1
Uniprot ID:
P35367
Molecular Weight:
55783.61 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Richelson E, Nelson A: Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther. 1984 Jul;230(1):94-102. [PubMed:6086881 ]
  3. Noguchi S, Inukai T, Kuno T, Tanaka C: The suppression of olfactory bulbectomy-induced muricide by antidepressants and antihistamines via histamine H1 receptor blocking. Physiol Behav. 1992 Jun;51(6):1123-7. [PubMed:1353628 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianser...
Gene Name:
ADRA2A
Uniprot ID:
P08913
Molecular Weight:
48956.275 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
  2. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  3. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Rotzinger S, Fang J, Baker GB: Trazodone is metabolized to m-chlorophenylpiperazine by CYP3A4 from human sources. Drug Metab Dispos. 1998 Jun;26(6):572-5. [PubMed:9616194 ]
  2. Kalgutkar AS, Henne KR, Lame ME, Vaz AD, Collin C, Soglia JR, Zhao SX, Hop CE: Metabolic activation of the nontricyclic antidepressant trazodone to electrophilic quinone-imine and epoxide intermediates in human liver microsomes and recombinant P4503A4. Chem Biol Interact. 2005 Jun 30;155(1-2):10-20. Epub 2005 Apr 18. [PubMed:15978881 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Wen B, Ma L, Rodrigues AD, Zhu M: Detection of novel reactive metabolites of trazodone: evidence for CYP2D6-mediated bioactivation of m-chlorophenylpiperazine. Drug Metab Dispos. 2008 May;36(5):841-50. doi: 10.1124/dmd.107.019471. Epub 2008 Jan 31. [PubMed:18238857 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
no
General Function:
Not Available
Specific Function:
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in the body. Appears to function in modulating the activity of the immune system during the acute-phase reaction.
Gene Name:
ORM1
Uniprot ID:
P02763
Molecular Weight:
23511.38 Da
References
  1. Ferry DG, Caplan NB, Cubeddu LX: Interaction between antidepressants and alpha 1-adrenergic receptor antagonists on the binding to alpha 1-acid glycoprotein. J Pharm Sci. 1986 Feb;75(2):146-9. [PubMed:2870173 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Stormer E, von Moltke LL, Perloff MD, Greenblatt DJ: P-glycoprotein interactions of nefazodone and trazodone in cell culture. J Clin Pharmacol. 2001 Jul;41(7):708-14. [PubMed:11452702 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 28, 2016 02:27